Tenecteplase in thrombolytic therapy of acute myocardial infarction:a rapid health technology evaluation
Objective To explore the application of the rapid health technology assessment(HTA)method to evaluate the efficacy,safety,and economy of tenecteplase in thrombolytic therapy in patients with acute myocardial infarction(AMI).Methods Searching national and international authoritative databases,to collect clinical evidence of teneplase in thrombolytic therapy of AMI.The search period was from the establishment of the database to September 5,2024.Two reviewers independently screened the evaluation literature and finally summarized and analyzed the result.Results A total of 9 articles were included,including 1 HTA report,5 systematic reviews/meta-analyses,and 3 pharmacoeconomic studies.In terms of effectiveness,the thrombolytic regeneration rate of teneplase was higher than those of urokinase and recombinant streptokinase(P<0.05),and the mortality,TIMI Ⅲ blood flow and all-cause mortality were not statistically significant compared with other drugs(P>0.05).In terms of safety,teneplase showed a relatively low risk of major bleeding compared to alteplase,and the rate of reinfarction was lower than that of accelerated infusion of alteplase(P<0.05).However,there was no significant difference between teneplase and other drugs in the incidence of reinfarction,non-fatal stroke,stroke,hemorrhagic stroke,intracranial hemorrhage and MACE(P>0.05).In terms of economy,teneplase has a good economic advantage in the thrombolytic therapy of AMI.Conclusion Teneplase has shown good efficacy,safety and economy in thrombolytic therapy of AMI patients,but the unit price and medical insurance need to be adjusted.
tenecteplaseacute myocardial infarctionefficacysafetyeconomyrapid health technology assessment
NETL
NSTL
万方数据
